Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 102 | 2024 | 11116 | 4.620 |
Why?
|
Prostate-Specific Antigen | 14 | 2024 | 2469 | 1.380 |
Why?
|
Polymorphism, Single Nucleotide | 51 | 2024 | 15879 | 1.340 |
Why?
|
Kallikreins | 3 | 2024 | 220 | 1.190 |
Why?
|
Genome-Wide Association Study | 22 | 2023 | 12666 | 1.070 |
Why?
|
Urinary Bladder, Overactive | 2 | 2024 | 115 | 0.980 |
Why?
|
Prostate | 11 | 2023 | 1770 | 0.950 |
Why?
|
Genetic Predisposition to Disease | 34 | 2024 | 17872 | 0.910 |
Why?
|
Selenium | 4 | 2016 | 417 | 0.830 |
Why?
|
Urinary Incontinence, Stress | 1 | 2024 | 181 | 0.790 |
Why?
|
Pregnancy-Associated Plasma Protein-A | 1 | 2021 | 60 | 0.770 |
Why?
|
Serine Endopeptidases | 5 | 2023 | 1021 | 0.710 |
Why?
|
Insulin-Like Growth Factor I | 4 | 2023 | 1931 | 0.650 |
Why?
|
Chromosomes, Human, Pair 8 | 6 | 2024 | 452 | 0.630 |
Why?
|
Fecal Incontinence | 1 | 2019 | 241 | 0.560 |
Why?
|
Metformin | 2 | 2014 | 907 | 0.510 |
Why?
|
Urinary Incontinence | 1 | 2019 | 489 | 0.500 |
Why?
|
PTEN Phosphohydrolase | 5 | 2021 | 1114 | 0.490 |
Why?
|
Metabolomics | 3 | 2021 | 1656 | 0.470 |
Why?
|
Follow-Up Studies | 25 | 2024 | 39108 | 0.460 |
Why?
|
Genotype | 25 | 2024 | 12982 | 0.460 |
Why?
|
Selenoprotein P | 1 | 2012 | 33 | 0.420 |
Why?
|
Male | 107 | 2024 | 360621 | 0.420 |
Why?
|
Genetic Variation | 12 | 2016 | 6571 | 0.400 |
Why?
|
Gene Expression Profiling | 8 | 2023 | 9414 | 0.380 |
Why?
|
Germ-Line Mutation | 5 | 2024 | 1858 | 0.370 |
Why?
|
Case-Control Studies | 31 | 2024 | 22124 | 0.370 |
Why?
|
Oncogene Proteins, Fusion | 7 | 2024 | 1605 | 0.370 |
Why?
|
Colonic Neoplasms | 2 | 2020 | 2534 | 0.370 |
Why?
|
Genetic Markers | 5 | 2022 | 2612 | 0.360 |
Why?
|
Aged | 63 | 2024 | 169179 | 0.340 |
Why?
|
Selenoproteins | 2 | 2016 | 215 | 0.340 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2019 | 2897 | 0.320 |
Why?
|
Repressor Proteins | 1 | 2019 | 2985 | 0.310 |
Why?
|
Prostatectomy | 8 | 2020 | 1824 | 0.310 |
Why?
|
Humans | 117 | 2024 | 761326 | 0.300 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2009 | 418 | 0.290 |
Why?
|
Neoplasm Staging | 10 | 2021 | 11098 | 0.290 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 3 | 2023 | 416 | 0.280 |
Why?
|
Nerve Tissue Proteins | 1 | 2019 | 4414 | 0.280 |
Why?
|
Risk Factors | 35 | 2024 | 74152 | 0.270 |
Why?
|
Tissue Array Analysis | 4 | 2021 | 550 | 0.270 |
Why?
|
Prospective Studies | 27 | 2024 | 54405 | 0.260 |
Why?
|
Middle Aged | 54 | 2024 | 220774 | 0.250 |
Why?
|
Gene Expression Regulation, Neoplastic | 10 | 2024 | 8527 | 0.250 |
Why?
|
Twins, Dizygotic | 2 | 2016 | 236 | 0.230 |
Why?
|
Disease Progression | 11 | 2024 | 13500 | 0.230 |
Why?
|
Prognosis | 13 | 2024 | 29588 | 0.220 |
Why?
|
Genetic Loci | 4 | 2021 | 2628 | 0.220 |
Why?
|
Proportional Hazards Models | 10 | 2024 | 12450 | 0.220 |
Why?
|
Urinary Incontinence, Urge | 1 | 2024 | 50 | 0.220 |
Why?
|
RNA, Messenger | 4 | 2017 | 12787 | 0.220 |
Why?
|
Organic Anion Transporters | 1 | 2024 | 101 | 0.220 |
Why?
|
Twins, Monozygotic | 2 | 2016 | 470 | 0.210 |
Why?
|
Receptors, Calcium-Sensing | 2 | 2015 | 318 | 0.210 |
Why?
|
Cohort Studies | 19 | 2024 | 41440 | 0.200 |
Why?
|
Choline | 1 | 2024 | 514 | 0.200 |
Why?
|
Superoxide Dismutase | 2 | 2015 | 592 | 0.190 |
Why?
|
DNA Repair-Deficiency Disorders | 1 | 2021 | 37 | 0.190 |
Why?
|
Vitamin D | 5 | 2024 | 3304 | 0.190 |
Why?
|
Hypoglycemic Agents | 1 | 2014 | 3082 | 0.180 |
Why?
|
Risk | 9 | 2021 | 9605 | 0.180 |
Why?
|
Aneuploidy | 1 | 2024 | 551 | 0.180 |
Why?
|
Aged, 80 and over | 19 | 2022 | 58946 | 0.180 |
Why?
|
Sex Hormone-Binding Globulin | 1 | 2022 | 550 | 0.170 |
Why?
|
Multifactorial Inheritance | 3 | 2023 | 1392 | 0.160 |
Why?
|
Confidence Intervals | 3 | 2021 | 2927 | 0.160 |
Why?
|
Serine Proteases | 1 | 2018 | 50 | 0.160 |
Why?
|
Linkage Disequilibrium | 8 | 2012 | 2004 | 0.150 |
Why?
|
Odds Ratio | 7 | 2021 | 9639 | 0.150 |
Why?
|
Receptors, Calcitriol | 3 | 2024 | 360 | 0.150 |
Why?
|
Quality of Life | 1 | 2019 | 13355 | 0.150 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2024 | 3244 | 0.150 |
Why?
|
Body Height | 2 | 2021 | 1570 | 0.150 |
Why?
|
Urinary Bladder | 1 | 2024 | 1150 | 0.150 |
Why?
|
Drug Eruptions | 1 | 2020 | 335 | 0.140 |
Why?
|
Environment | 1 | 2023 | 1122 | 0.140 |
Why?
|
Genetic Association Studies | 4 | 2021 | 2724 | 0.140 |
Why?
|
DNA Modification Methylases | 1 | 2018 | 210 | 0.140 |
Why?
|
Transurethral Resection of Prostate | 1 | 2017 | 79 | 0.140 |
Why?
|
Extracellular Matrix Proteins | 1 | 2021 | 828 | 0.140 |
Why?
|
Squalene Monooxygenase | 1 | 2016 | 11 | 0.140 |
Why?
|
Inheritance Patterns | 1 | 2019 | 340 | 0.140 |
Why?
|
Glutathione Peroxidase | 2 | 2016 | 257 | 0.130 |
Why?
|
Age Factors | 3 | 2022 | 18401 | 0.130 |
Why?
|
Risk Assessment | 13 | 2024 | 23981 | 0.130 |
Why?
|
Neurosecretory Systems | 1 | 2017 | 223 | 0.130 |
Why?
|
Quantitative Trait Loci | 3 | 2019 | 2105 | 0.130 |
Why?
|
Chromosome Mapping | 5 | 2018 | 4638 | 0.130 |
Why?
|
DNA Repair Enzymes | 1 | 2018 | 346 | 0.130 |
Why?
|
Haplotypes | 8 | 2018 | 2774 | 0.130 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2019 | 857 | 0.130 |
Why?
|
Neoplasm Invasiveness | 3 | 2021 | 3588 | 0.130 |
Why?
|
Diabetes Mellitus | 1 | 2014 | 5841 | 0.120 |
Why?
|
Endometrial Neoplasms | 1 | 2024 | 1365 | 0.120 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2019 | 10203 | 0.120 |
Why?
|
Molecular Epidemiology | 2 | 2014 | 468 | 0.120 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 3806 | 0.120 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2021 | 1650 | 0.120 |
Why?
|
Insulin-Like Growth Factor Binding Protein 1 | 2 | 2023 | 127 | 0.120 |
Why?
|
Signal Transduction | 4 | 2024 | 23427 | 0.120 |
Why?
|
Breast Neoplasms | 9 | 2022 | 21009 | 0.120 |
Why?
|
Genes, BRCA1 | 2 | 2010 | 764 | 0.110 |
Why?
|
Survival Analysis | 4 | 2015 | 10075 | 0.110 |
Why?
|
Electroretinography | 1 | 2016 | 524 | 0.110 |
Why?
|
Interleukin-4 | 1 | 2018 | 1149 | 0.110 |
Why?
|
Body Mass Index | 5 | 2021 | 12949 | 0.110 |
Why?
|
Catalase | 1 | 2014 | 217 | 0.110 |
Why?
|
Genes, myc | 2 | 2017 | 390 | 0.110 |
Why?
|
Models, Statistical | 2 | 2021 | 5078 | 0.110 |
Why?
|
Translocation, Genetic | 1 | 2018 | 1393 | 0.110 |
Why?
|
Cell Cycle Proteins | 1 | 2024 | 3448 | 0.110 |
Why?
|
Epigenomics | 1 | 2018 | 941 | 0.100 |
Why?
|
DNA Repair | 1 | 2021 | 2044 | 0.100 |
Why?
|
Hearing Loss, Sensorineural | 1 | 2018 | 781 | 0.100 |
Why?
|
Sweden | 3 | 2024 | 1379 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2017 | 988 | 0.100 |
Why?
|
Adult | 21 | 2024 | 221122 | 0.100 |
Why?
|
Stromal Cells | 1 | 2017 | 1330 | 0.100 |
Why?
|
Vitamin E | 1 | 2016 | 871 | 0.100 |
Why?
|
Metabolome | 1 | 2018 | 987 | 0.100 |
Why?
|
Receptors, Adiponectin | 1 | 2011 | 81 | 0.100 |
Why?
|
Mendelian Randomization Analysis | 3 | 2023 | 1005 | 0.100 |
Why?
|
Early Detection of Cancer | 3 | 2023 | 3200 | 0.090 |
Why?
|
Disease-Free Survival | 2 | 2019 | 6815 | 0.090 |
Why?
|
Prostatic Secretory Proteins | 1 | 2010 | 24 | 0.090 |
Why?
|
Receptor, IGF Type 1 | 1 | 2013 | 378 | 0.090 |
Why?
|
Promoter Regions, Genetic | 2 | 2021 | 5778 | 0.090 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2020 | 2859 | 0.090 |
Why?
|
Cholesterol | 2 | 2018 | 2902 | 0.090 |
Why?
|
Energy Intake | 1 | 2018 | 2134 | 0.090 |
Why?
|
Neoplasms | 2 | 2016 | 22158 | 0.090 |
Why?
|
Nuclear Receptor Coactivators | 1 | 2010 | 61 | 0.090 |
Why?
|
Genetics, Population | 2 | 2006 | 939 | 0.090 |
Why?
|
Chromosomes, Human, Pair 10 | 1 | 2010 | 277 | 0.090 |
Why?
|
Tumor Microenvironment | 1 | 2023 | 3873 | 0.090 |
Why?
|
Mass Spectrometry | 1 | 2017 | 2193 | 0.080 |
Why?
|
Logistic Models | 3 | 2021 | 13251 | 0.080 |
Why?
|
Gene Fusion | 1 | 2012 | 356 | 0.080 |
Why?
|
Oligonucleotide Array Sequence Analysis | 3 | 2017 | 3777 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2018 | 2453 | 0.080 |
Why?
|
Adenocarcinoma | 2 | 2018 | 6332 | 0.080 |
Why?
|
ROC Curve | 1 | 2016 | 3572 | 0.080 |
Why?
|
Endoribonucleases | 1 | 2010 | 228 | 0.080 |
Why?
|
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2010 | 507 | 0.080 |
Why?
|
Double-Blind Method | 2 | 2013 | 12329 | 0.080 |
Why?
|
Paraffin Embedding | 2 | 2020 | 302 | 0.070 |
Why?
|
Tumor Suppressor Proteins | 1 | 2018 | 2804 | 0.070 |
Why?
|
Toll-Like Receptor 4 | 1 | 2011 | 579 | 0.070 |
Why?
|
Epithelial Cells | 2 | 2017 | 3666 | 0.070 |
Why?
|
Energy Metabolism | 1 | 2018 | 2879 | 0.070 |
Why?
|
Molecular Sequence Annotation | 2 | 2021 | 523 | 0.070 |
Why?
|
DNA-Binding Proteins | 1 | 2024 | 9605 | 0.070 |
Why?
|
Sequence Tagged Sites | 1 | 2006 | 96 | 0.070 |
Why?
|
Alleles | 5 | 2024 | 6909 | 0.070 |
Why?
|
Mutation, Missense | 4 | 2010 | 2570 | 0.070 |
Why?
|
Incidence | 6 | 2024 | 21336 | 0.070 |
Why?
|
Gene Dosage | 1 | 2010 | 1218 | 0.070 |
Why?
|
Receptors, Transforming Growth Factor beta | 1 | 2007 | 302 | 0.070 |
Why?
|
Immunohistochemistry | 4 | 2014 | 11070 | 0.070 |
Why?
|
Antioxidants | 1 | 2014 | 1670 | 0.070 |
Why?
|
DNA | 1 | 2019 | 7216 | 0.060 |
Why?
|
Adiponectin | 1 | 2011 | 1113 | 0.060 |
Why?
|
Obesity | 3 | 2018 | 12934 | 0.060 |
Why?
|
Transcription, Genetic | 2 | 2017 | 7597 | 0.060 |
Why?
|
Survival Rate | 3 | 2020 | 12710 | 0.060 |
Why?
|
C-Reactive Protein | 2 | 2014 | 3824 | 0.060 |
Why?
|
Head and Neck Neoplasms | 1 | 2019 | 2891 | 0.060 |
Why?
|
Androgen Antagonists | 2 | 2024 | 1410 | 0.060 |
Why?
|
Hypertension | 1 | 2024 | 8539 | 0.060 |
Why?
|
Precancerous Conditions | 1 | 2010 | 978 | 0.060 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2007 | 628 | 0.060 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2024 | 349 | 0.060 |
Why?
|
BRCA1 Protein | 1 | 2010 | 1155 | 0.050 |
Why?
|
Europe | 2 | 2024 | 3420 | 0.050 |
Why?
|
Trans-Activators | 1 | 2012 | 2858 | 0.050 |
Why?
|
Receptor, Muscarinic M3 | 1 | 2022 | 37 | 0.050 |
Why?
|
Marital Status | 1 | 2024 | 426 | 0.050 |
Why?
|
Time Factors | 3 | 2019 | 39974 | 0.050 |
Why?
|
Calcium | 1 | 2015 | 5726 | 0.050 |
Why?
|
Receptors, Purinergic | 1 | 2022 | 66 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 11735 | 0.050 |
Why?
|
Female | 15 | 2024 | 392485 | 0.050 |
Why?
|
Ovarian Neoplasms | 1 | 2019 | 4877 | 0.050 |
Why?
|
Biopsy | 2 | 2024 | 6768 | 0.050 |
Why?
|
Gene Expression | 1 | 2014 | 7582 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2023 | 313 | 0.050 |
Why?
|
Cholinergic Antagonists | 1 | 2022 | 168 | 0.050 |
Why?
|
Life Style | 2 | 2024 | 3915 | 0.050 |
Why?
|
United States | 7 | 2024 | 72317 | 0.050 |
Why?
|
Receptors, Cholinergic | 1 | 2022 | 241 | 0.050 |
Why?
|
Insulin-Like Growth Factor II | 1 | 2023 | 269 | 0.050 |
Why?
|
Reproducibility of Results | 2 | 2016 | 20092 | 0.050 |
Why?
|
Genes, BRCA2 | 1 | 2004 | 601 | 0.050 |
Why?
|
Carrier Proteins | 1 | 2014 | 4936 | 0.050 |
Why?
|
TRPV Cation Channels | 1 | 2022 | 243 | 0.050 |
Why?
|
Stathmin | 1 | 2020 | 70 | 0.040 |
Why?
|
Bone Neoplasms | 1 | 2012 | 2527 | 0.040 |
Why?
|
Fanconi Anemia | 1 | 2021 | 324 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 2019 | 6901 | 0.040 |
Why?
|
DNA Mismatch Repair | 1 | 2021 | 428 | 0.040 |
Why?
|
Predictive Value of Tests | 3 | 2021 | 15262 | 0.040 |
Why?
|
Receptors, Androgen | 1 | 2004 | 1078 | 0.040 |
Why?
|
Medical History Taking | 1 | 2022 | 773 | 0.040 |
Why?
|
Registries | 3 | 2024 | 8223 | 0.040 |
Why?
|
Chromosomes, Human, Pair 2 | 1 | 2018 | 313 | 0.040 |
Why?
|
Diet, Mediterranean | 1 | 2024 | 740 | 0.030 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 2018 | 430 | 0.030 |
Why?
|
Retrospective Studies | 3 | 2022 | 80575 | 0.030 |
Why?
|
Hawaii | 2 | 2006 | 102 | 0.030 |
Why?
|
Androgens | 1 | 2024 | 1286 | 0.030 |
Why?
|
Thioredoxin Reductase 2 | 1 | 2016 | 25 | 0.030 |
Why?
|
Thioredoxin Reductase 1 | 1 | 2016 | 32 | 0.030 |
Why?
|
Selenium-Binding Proteins | 1 | 2016 | 18 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 2020 | 2468 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2021 | 12059 | 0.030 |
Why?
|
Seasons | 2 | 2012 | 1519 | 0.030 |
Why?
|
Tissue Fixation | 1 | 2017 | 241 | 0.030 |
Why?
|
Fluorouracil | 1 | 2020 | 1637 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2010 | 5297 | 0.030 |
Why?
|
Phospholipids | 1 | 2018 | 786 | 0.030 |
Why?
|
Germ Cells | 1 | 2018 | 634 | 0.030 |
Why?
|
Cell Line, Tumor | 2 | 2024 | 16966 | 0.030 |
Why?
|
DNA Damage | 1 | 2024 | 2442 | 0.030 |
Why?
|
Norway | 1 | 2016 | 498 | 0.030 |
Why?
|
Finland | 1 | 2016 | 608 | 0.030 |
Why?
|
Social Class | 1 | 2023 | 2005 | 0.030 |
Why?
|
Trypsin Inhibitor, Kazal Pancreatic | 1 | 2014 | 30 | 0.030 |
Why?
|
Lung Neoplasms | 1 | 2019 | 13333 | 0.030 |
Why?
|
INDEL Mutation | 1 | 2015 | 267 | 0.030 |
Why?
|
Social Support | 1 | 2024 | 2172 | 0.030 |
Why?
|
Microsatellite Repeats | 2 | 2007 | 785 | 0.030 |
Why?
|
Phenotype | 3 | 2019 | 16603 | 0.030 |
Why?
|
Cell Differentiation | 1 | 2011 | 11531 | 0.030 |
Why?
|
Residence Characteristics | 1 | 2023 | 2092 | 0.030 |
Why?
|
Neoplasm Metastasis | 2 | 2017 | 4908 | 0.030 |
Why?
|
Denmark | 1 | 2016 | 770 | 0.030 |
Why?
|
Watchful Waiting | 1 | 2017 | 491 | 0.030 |
Why?
|
Retinoid X Receptor alpha | 1 | 2012 | 16 | 0.030 |
Why?
|
Epithelium | 1 | 2017 | 1603 | 0.030 |
Why?
|
Mice | 4 | 2024 | 81474 | 0.030 |
Why?
|
25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2012 | 58 | 0.030 |
Why?
|
Steroid Hydroxylases | 1 | 2012 | 96 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2018 | 1791 | 0.020 |
Why?
|
Biological Transport | 1 | 2016 | 2090 | 0.020 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2015 | 9275 | 0.020 |
Why?
|
Testosterone | 1 | 2022 | 2472 | 0.020 |
Why?
|
Vitamin D-Binding Protein | 1 | 2012 | 131 | 0.020 |
Why?
|
Triglycerides | 1 | 2018 | 2458 | 0.020 |
Why?
|
Australia | 1 | 2014 | 1246 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2018 | 2329 | 0.020 |
Why?
|
Waist Circumference | 1 | 2013 | 934 | 0.020 |
Why?
|
Nuclear Proteins | 1 | 2024 | 5794 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2023 | 7824 | 0.020 |
Why?
|
Self Report | 1 | 2021 | 3724 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2020 | 2448 | 0.020 |
Why?
|
Algorithms | 2 | 2020 | 14025 | 0.020 |
Why?
|
Ki-67 Antigen | 1 | 2010 | 629 | 0.020 |
Why?
|
Animals | 4 | 2024 | 168388 | 0.020 |
Why?
|
Mass Screening | 1 | 2023 | 5428 | 0.020 |
Why?
|
Gene Rearrangement | 1 | 2012 | 1125 | 0.020 |
Why?
|
Body Weight | 1 | 2017 | 4614 | 0.020 |
Why?
|
Bone and Bones | 1 | 2017 | 2568 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2019 | 3611 | 0.020 |
Why?
|
RNA, Neoplasm | 1 | 2009 | 749 | 0.020 |
Why?
|
Human Genome Project | 1 | 2006 | 200 | 0.020 |
Why?
|
Chromosomes, Human, Pair 7 | 1 | 2006 | 310 | 0.020 |
Why?
|
Los Angeles | 1 | 2006 | 243 | 0.020 |
Why?
|
Reference Values | 1 | 2012 | 4921 | 0.020 |
Why?
|
DNA Primers | 1 | 2009 | 2820 | 0.020 |
Why?
|
Up-Regulation | 1 | 2013 | 4120 | 0.010 |
Why?
|
Cell Adhesion | 1 | 2010 | 3089 | 0.010 |
Why?
|
DNA, Neoplasm | 1 | 2009 | 1745 | 0.010 |
Why?
|
Loss of Heterozygosity | 1 | 2006 | 662 | 0.010 |
Why?
|
Introns | 1 | 2006 | 981 | 0.010 |
Why?
|
Inflammation | 1 | 2023 | 10760 | 0.010 |
Why?
|
Vitamins | 1 | 2012 | 1635 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2018 | 14409 | 0.010 |
Why?
|
Treatment Outcome | 3 | 2015 | 64645 | 0.010 |
Why?
|
California | 1 | 2006 | 1426 | 0.010 |
Why?
|
Gene Frequency | 1 | 2009 | 3639 | 0.010 |
Why?
|
Smoking | 1 | 2019 | 9051 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2018 | 7999 | 0.010 |
Why?
|
Exons | 1 | 2006 | 2392 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2010 | 3210 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2009 | 6086 | 0.010 |
Why?
|
Genomics | 1 | 2015 | 5817 | 0.010 |
Why?
|
Mental Disorders | 1 | 2019 | 6839 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2024 | 36430 | 0.010 |
Why?
|
Population Surveillance | 1 | 2006 | 2603 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2010 | 10431 | 0.010 |
Why?
|
Base Sequence | 1 | 2004 | 12449 | 0.010 |
Why?
|
Genome, Human | 1 | 2006 | 4423 | 0.010 |
Why?
|
MicroRNAs | 1 | 2009 | 3796 | 0.010 |
Why?
|
Computer Simulation | 1 | 2006 | 6236 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2009 | 15835 | 0.010 |
Why?
|
Mutation | 1 | 2010 | 30044 | 0.000 |
Why?
|